anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The SINUVA Sinus Implant was evaluated in 450 patients, 18 years of age and older, with chronic rhinosinusitis with nasal polyps and a history of ethmoid sinus surgery. The development program included a trial of 6 months duration (Study 1: NCT01732536), another trial of 90 days duration (Study 2: NCT02291549), and a repeat placement study of 1-year duration (Study 3: NCT03358329) [see Adverse Reactions (6.1)]. The efficacy of SINUVA Sinus Implant is based primarily on Study 2 as described below.

Study 2 was a randomized, controlled, single-blind, multicenter (all sites were in the US) study with 300 patients: 201 patients were assigned to the treatment group and underwent bilateral placement of the SINUVA Sinus Implants in the ethmoid sinuses. The remaining 99 patients were assigned to the control group and underwent a placebo (sham) procedure, consisting of advancement of the Delivery System with the SINUVA Sinus Implant into the ethmoid sinuses, followed by removal of the Delivery System without deployment of the SINUVA Sinus Implant. The Implants were removed by Day 60 to allow blinded grading at Day 90. All patients [treatment (T) and control (C) groups] were required to use a mometasone furoate nasal spray once daily (200 mcg of mometasone furoate) through Day 90.

The co-primary efficacy endpoints were:

  * Change from baseline to Day 30 in Nasal Obstruction/Congestion score, as determined by patients using a daily diary; and
  * Change from baseline to Day 90 in bilateral polyp grade, as determined from video- endoscopies reviewed by an independent panel of 3 sinus surgeons who were masked to treatment assignment.



The study population consisted of adult patients (≥ 18 years of age) diagnosed with chronic rhinosinusitis who had undergone prior bilateral total ethmoidectomy but were indicated for revision endoscopic sinus surgery because they presented with recurrent nasal obstruction/congestion symptoms and recurrent bilateral sinus obstruction due to nasal polyps. Subjects were excluded for other grade 3 or 4 adhesions/synechiae, grade 4 polyps, acute bacterial or invasive fungal sinusitis, and immune deficiency, including cystic fibrosis. There were no statistically significant differences between groups in baseline demographics and clinical characteristics, except the treatment group had a higher proportion of asthma patients (T: 74% vs. C: 62%) and higher mean Percent Ethmoid Sinus Obstruction score [T: 76 (SD 17.4) vs. C: 69 (SD 19.9)]. The random imbalances did not impact treatment effect.

The co-primary efficacy results are presented in Table 2. The treatment group demonstrated a statistically significant difference from baseline to Day 30 in Nasal Obstruction/Congestion score and from baseline to Day 90 in bilateral polyp grade, compared to the control group.

Change from baseline to Day 90 in the mean Percent Ethmoid Sinus Obstruction score (100 mm VAS), as judged by the independent panel [Difference vs. control: -7.96%; 95% CI (-12.1, -3.8)], met statistical significance and supported the co-primary endpoints.
PURPOSE:To obtain a new compound useful for treating diseases such as glomerular nephritis, ulcerative colitis, asthma, allergic rhinitis, cardiac infarction and thrombosis to which inflammatory cell participates, because of strong neutrophil migration-suppressing action. CONSTITUTION:A compound of formula I (R is 1-3C alkyl) and its salt, e.g. (E)-2-isopropyl-3-(2-(3-pyridyl)vinyl)pyrozolo[1,5-a]pyridine.hydrochl oride. This compound is obtained by reacting a compound of formula II with a compound of formula III, preferably in an organic solvent such as THF in the presence of a base such as sodium alkoxide. Furthermore, the reaction temperature is preferably from -60 deg.C to reflux temperature of the solvent. The compound of formula II which is a new compound is preferably obtained by reducing a compound of formula IV with sodium borohydride in methanol or ethanol to afford an alcohol compound and reacting the compound with triphenyl phosphine and carbon tetrachloride at reflux temperature.
BACKGROUND: Untreated acute ankle sprains often result in chronic ankle instability (CAI) and can ultimately lead to the development of post-traumatic osteoarthritis (PTOA). At present, a typical animal model of ankle instability in mice is established by transecting the ligaments around the ankle joint. This study aimed to establish a grade I acute ankle sprain animal model by rapid stretching of peri-ankle joint ligaments. Furthermore, we tried to explore the pathophysiological mechanism of ankle osteoarthritis.
METHODS: In all, 18 male C57BL/6 J mice (7 weeks) were randomly divided into three groups: calcaneofibular ligament (CFL) laxity group, deltoid ligament (DL) laxity group, and SHAM group. One week after the surgical procedure, all mice were trained to run in the mouse rotation fatigue machine daily. The mice were tested on the balance beam before surgery and three days, 4 weeks, 8 weeks, and 12 weeks after surgery. Footprint analyses were performed on each mouse before surgery and 12 weeks after surgery. Micro-CT scanning was then performed to evaluate the degeneration of ankle joints and histological staining was performed to analyze and evaluate PTOA caused by ankle joint instability.
RESULTS: After surgery, the mice in the CFL and DL laxity groups took longer to cross the balance beam and slipped more often than those in the SHAM group (p < 0.05). The step length and width in the CFL and DL laxity groups were significantly shorter and smaller than those in the SHAM group 12 weeks after surgery (p < 0.05). There was a significant increase in the bone volume fraction (BV/TV) in the CFL and DL laxity groups compared with the SHAM group (p < 0.05). Histological staining results suggested obvious signs of PTOA in the CFL and DL laxity groups.
CONCLUSIONS: Based on CFL and DL laxity in a mouse ankle instability model, this study suggests that grade I ankle sprain can contribute to chronic ankle instability, impair motor coordination and balance, and eventually lead to PTOA of ankle with significant degeneration of its adjacent joints.
With overdosage, a curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis). It should not be given to patients with myasthenia gravis except to reduce adverse muscarinic effects of an anticholinesterase [see Error! Hyperlink reference not valid. (Error! Hyperlink reference not valid.)].
Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for major depressive disorder, but remission rates are 20-40%, and ideal stimulation parameters are unknown. rTMS is thought to work by changing the synaptic strength of neurons. The ability of the brain to make these changes is referred to as plasticity. rTMS-induced changes are thought to build with successive treatment sessions, a process referred to as metaplasticity. While both plasticity and metaplasticity are well-established in single cell physiology, relevance to rTMS in humans remains unknown. To improve clinical efficacy, the investigators need to understand 1) the neural response to a single rTMS session (plasticity), 2) the neural response to repeated daily rTMS sessions (metaplasticity), and 3) whether computational models of plasticity based on single-cell physiology apply to human patients receiving rTMS for depression.

Goals of the study are to 1) establish a detailed mechanistic understanding of the brain changes during current rTMS treatment; 2) identify clinically meaningful electrophysiological biomarkers for rTMS treatment; 3) establish a computational model to help predict both brain and clinical changes.
The present invention discloses a spleen and stomach deficiency-cold adjuvant treating composition and a preparation method thereof. The composition comprises the following raw materials: 47-82 parts of grilled ginger, 10-30 parts of red dates, 5-15 parts of pepper and 3-8 parts of licorice. The present invention further discloses a preparation method for the composition. The composition of the invention can be prepared according to the conventional methods in the field of Chinese medicine preparations into suitable oral preparations, such as pulvis, granules, powders, oral liquids, etc.; or prepared into health-care products or food. The fresh ginger raw materials are grilled using a specific method which effectively increases the content of a variety of human body suitable trace elements in the ginger, and the adjuvant treating composition has efficacies of harmonizing spleen and stomach, warming stomach and stopping cough, removing dampness and expelling cold, etc. after adding red dates, licorice and pepper. The composition of the invention does not have any toxic or side effects, is a pure natural adjuvant food, and provides a safe and reliable adjuvant treating food for groups with the above symptoms caused by deficiency-cold spleen and stomach.
From 28 to 33 weeks' gestation, significant neurological reorganization takes place, initiating fetal behavioral individuality and capacity for extrauterine survival. Infants born at this transitional stage exhibit unexpectedly significant brain dysfunction as they develop and age. The majority of these infants will develop psychomotor, cognitive, and attentional function deficits as well as emotional vulnerability and substandard school performance. Research suggests that these symptoms are due to a central deficit in frontal lobe processing of complex information. This central deficit may result from increased vulnerability of cerebral white matter during the last trimester of gestation, its phase of most rapid development. Persistent stress due to inappropriate sensory stimulation may contribute to alteration of early brain structure and function. This study will identify specific adaptations of the preterm brain to the transient NICU experience in order to estimate the potential of such experience in remodeling neuroanatomical structure and neurodevelopmental function. Further, the study will evaluate a program of specialized developmental care within the NICU environment.

The study's specialized developmental care model views the preterm infant as a fetus and attempts to reduce the discrepancy between the technological hospital environment and the mother's womb. A developmental specialist team will support the NICU caregivers. The developmental specialists will observe the infant's behavior and use these observations to formulate descriptive neurobehavioral reports and suggestions, to structure caregiving procedures in coordination with the infant's sleep/wake cycle, and to maintain the infant's well-regulated behavioral balance. The goal of the intervention is to promote the infant's strengths while reducing the infant's self-regulatory vulnerability.

Sixty medically healthy infants born between 28 and 33 weeks' gestation will be randomly assigned to standard NICU care or specialized developmental care. Preterm infants will be compared to 30 healthy full term infants. All infants will be assessed at 42 weeks' postconceptional age in three neurodevelopmental domains: neurobehavioral function, neuroelectrophysiological function, and neuroanatomic structure. Assessments will focus on distinct regions of the brain (occipital and frontal lobes) and the corpus callosum (which connects the right and left sides of the brain).
Treatment Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will receive 150 mg Mg (0.3 mL-the intervention) in the block.
PCT No. PCT/US93/10950 Sec. 371 Date Apr. 1, 1997 Sec. 102(e) Date Apr. 1, 1997 PCT Filed Nov. 12, 1993 PCT Pub. No. WO94/10989 PCT Pub. Date May 26, 1994A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human  alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human  alpha 1A adrenergic receptor, a human  alpha 1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human  alpha 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such  alpha 1C adrenergic receptor. Compounds meeting these criteria are provided.
Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest.
Organosilicon compounds of the average general formula <FORM:0802467/III/1> in which each R is a monovalent hydrocarbon radical, R1 is an alkylene radical, each R11 is an alkylene radical containing at least 2 carbon atoms, n has a value of at least 1. R111 is hydrogen, a saturated hydrocarbon or acyl hydrocarbon radical and a has a value from 0 to 3 inclusive (see Group IV (a)), are used as anti-foaming agents.  The products of Examples (1) and (2) are good anti-foam agents for ethylene glycol anti-freeze solutions.ALSO:Organosilicon compounds of the average general formula <FORM:0802467/IV (a)/1> in which each R is a monovalent hydrocarbon radical, R1 is an alkylene radical, each R11 is an alkylene radical containing at least 2 carbon atoms, n has a value of at least 1, R111 is hydrogen, a saturated hydrocarbon radical or an aryl hydrocarbon radical, and a  has a value from 0 to 3 inclusive, may be made (i) by reacting an unsaturated ether of the general formula R111(OR11)nOB, in which B is an alkenyl radical, with an organosilane or siloxane containing an Si-H group, preferably in the presence of catalysts such as organic peroxides, platinum or chloroplatinic acid.  Where R111 is hydrogen it is preferable to block the OH group in the unsaturated ether with a triorganosiloxy group prior to reaction with the silane or siloxane; or (ii) by reacting a hydroxyalkyl silane or siloxane with an alkylene oxide at 70 DEG  to 150 DEG  C. in the presence of catalysts such as H2SO4, SnCl4 and AlCl3.  The R radicals specified are alkyl, cycloaliphatic, aryl, aralkyl or unsaturated aliphatic.  The novel siloxanes may be copolymerized with conventional siloxanes containing silicon-bonded hydrocarbon or halogenated hydrocarbon radicals.  In typical examples: (1) polyglycol A was reacted with trimethylchlorosilane and the resulting trimethylsiloxy-blocked product was then reacted with a trimethyl end-blocked methylhydrogensiloxane in the presence of chloroplatinic acid. The product was then hydrolysed to remove the trimethylsiloxy groups from the glycol side chain and purified to yield a water-soluble liquid of the formula <FORM:0802467/IV (a)/2> (5) the vinyl ether of ethylene glycol was reacted with tetramethyldisiloxane in toluene and in the presence of chloroplatinic acid to give the compound <FORM:0802467/IV (a)/3>  Uses.-The products are useful as emulsifying agents, e.g. for phenylmethylsiloxanes, anti-foaming agents, mould-release agents, lubricants and as cosmetic additives.
Ablation of Cyp27b1 eliminates calcitriol but does not disturb fetal mineral homeostasis or skeletal development. However, independent of fetal genotypes, maternal loss of Cyp27b1 altered fetal mineral and hormonal levels compared to offspring of WT dams. We hypothesized that these maternal influences would alter postnatal skeletal development. Cyp27b1 null and WT females were mated to bear only Cyp27b1+/- offspring. Forty-eight hours after birth, pups were cross-fostered to dams of the same or opposite genotype that bore them. Maternal and offspring samples were collected on days 21 (weaning) and 42. Offspring measurements included minerals and hormones, BMC by DXA, ash weight and mineral content, gene expression, 3-point bending tests, and microCT. Maternal lactational behavior was evaluated. Milk was analyzed for nutritional content. At day 21, offspring fostered by nulls, independent of birth dam, had ~20% lower weight, BMC, ash weight, and ash calcium than pups fostered by WT dams. Adjustment for body weight accounted for the lower BMC but not the lower ash weight and ash calcium. Hormones and serum/urine minerals did not differ across offspring groups. Offspring fostered by nulls had shorter femurs and lower cortical thickness, mean polar moment of inertia, cortical area, trabecular bone volume, and trabecular number. Dam lactational behaviors and milk nutritional content did not differ between groups. At day 42, body weight, ash weight, lengths, BMC, and tibial bone strength were no longer different between pups fostered by null vs WT dams. In summary, pups fostered by Cyp27b1 nulls, regardless of birth dam, have proportionately smaller skeletons at 21 d, impaired microstructure, but normal mineral homeostasis. The skeletal effects are largely recovered by day 42 (3 wk after weaning). In conclusion, maternal loss of calcitriol impairs early postnatal cortical bone growth and trabecular bone mass, but affected offspring catch up after weaning.
The aim was to determine the association between plaque and gingival inflammation reported by dietary interventions. Data of four clinical studies dealing with changed nutrition and gingival examination were reanalyzed with regard to gingival inflammation (GI), plaque (PI), and bleeding on probing (BOP). Dietary changes basically involved avoiding sugar, white flour and sweetened drinks and focusing on whole foods for 4 weeks. The control groups were to maintain their usual diet. All participants had to reduce their oral hygiene efforts. Linear regression models taking the clustering of the data due to several studies into account were applied. In total, data of 92 participants (control groups: 39, test-groups 53) were reanalyzed. While both groups showed a slight increase in dental plaque, only the test groups showed a significant decrease in inflammatory parameters: GI (mean value difference End-Baseline (Δ): -0.31 (±SD 0.36)) and BOP (Δ: -15.39% (±16.07)), both p < 0.001. In the control groups, there was a constant relation between PI and GI, while the experimental group showed a decreasing relationship in GI/PI (p = 0.016), and even an inverted relationship BOP/PI under a changed diet (p = 0.031). In conclusion, diet seems to be a determining factor how the gingiva reacts towards dental plaque.
Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
The sciatic nerve block is frequently used for anesthesia or analgesia for surgery of the lower extremities. Ultrasound-guided sciatic nerve blocks performed at the lateral mid-femoral level have been successfully described with subjects in the supine position and the lower limb elevated in order to accommodate the ultrasound probe against the posterior aspect of the thigh. In the pediatric setting in which nerve blocks are commonly performed with the patient anesthetized rather than awake, we find this technique to be unwieldy as a single-operator technique. Using a more ergonomic approach that has not been previously described, we plan to identify and describe the sciatic nerve with the ultrasound positioned against the lateral aspect of the thigh. We hope to describe the appearance of the sciatic nerve and its location in relation to adjacent anatomic structures using this modified approach.

This a prospective cross-sectional study of 40 pediatric subjects 11-17 years of age. Three ultrasound images of the sciatic nerve will be obtained via the lateral mid-thigh approach in 40 pediatric patients scheduled to undergo sciatic nerve block - the first image prior to placement of the block, the second after the nerve is located by the stimulating needle and the third after the injection of local anesthetic.
BACKGROUND: Enterococcus faecium (E. faecium) stands as a prominent pathogen contributing to Gram-positive bacterial infections in individuals who have undergone liver transplantation.
CASE PRESENTATION: A 66-year-old male with a three-year history of treated anxiety disorder was admitted to our hospital due to recurrent abdominal distension and oliguria. He was diagnosed with hepatic veno-occlusive disease (HVOD), hepatic failure, pneumonia, renal insufficiency and abdominal ascites. A liver transplantation procedure was performed, but the patient's infection index increased on the first day after surgery. Empirical antibiotic therapy with ceftriaxone and meropenem and preventive antifungal therapy were applied. Sputum culture, blood culture, ascites culture and bronchoalveolar lavage fluid (BALF) next-generation sequencing (NGS), revealed the presence of E. faecium. Given the application of various nephrotoxic immunosuppressive agents after liver transplantation, pre-existing renal insufficiency, severe bone marrow suppression, and a history of anxiety disorder treated with sertraline, contezolid was added for the treatment of the Gram-positive bacterial infection. Sixteen days after surgery, cultures from ascites and sputum yielded negative results for fungi and bacteria. Contezolid was subsequently discontinued without any reported adverse events during follow-up.
CONCLUSION: Treatment with contezolid as the first-line therapy for sepsis and pneumonia caused by E. faecium following liver transplantation has shown satisfactory efficacy and safety. Therefore, contezolid may hold great promise for managing this life-threatening condition.
At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
There are two types of embryo transfers; fresh and frozen embryo transfers. Studies have been conducted to compare success rates between fresh and frozen embryo transfers. However, most studies have not taken into consideration women's quality of life, sexual life and psychological state in comparing fresh embryo transfer with frozen embryo transfers. These all parameters are confounding factors that may influence the success of embryo transfer. The purpose of this study is to compare women's quality of life, sexual life and psychological state using validated forms between those undergoing fresh embryo transfer and those undergoing frozen embryo transfer. The following forms will be used: expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI. This study can provide evidence regarding the association between women's quality of life, sexual life and psychological state and embryo transfer success.
Intervention Group First, pre-tests were applied to the women in the experimental group. A 4-week training program created by taking into account the cultural characteristics of Syrian women; Explaining breast health, Explaining breast structure, Cancer, Breast cancer, Early diagnosis and its importance, BSE application, CBE and mammography, Barriers on breast cancer, Cancer Early Diagnosis, Screening and Education Center. A 'Nurse-directed screening counseling telephone support line' will be established for the women in the experimental group. Then, motivational interviews will be applied to the women in the experimental group by the researcher, who emphasizes the importance of early diagnosis in line with the health belief model. Reminders will be made by phone every week in the 3rd month. The final tests will be held 4 months after the end of the training.